Leal Health establishes proprietary platform for oncologists to obtain personalized clinical trial matches for patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Leal, formerly known as Trialjectory, has established a proprietary platform for oncologists to quickly identify personalized clinical trial matches for their patients, reducing reliance on unstructured data and expediting patient treatment identification / clinical trial enrollment. The platform is free for oncologists. 

Leal is an AI-powered decision support platform that aims to democratize patient access to advanced cancer treatments. Its goal is to allow the pharmaceutical and biotech industry to execute patient-centric clinical trials

Leveraging AI, Leal’s technology identifies relevant and available clinical trial options for oncologists to present to their patients. It also allows oncologists to customize clinical trial searches through specifying cancer subtypes, biomarkers. and other criteria.

“Traditionally, oncologists have relied on either the major academic centers in the U.S. or on ClinicalTrials.gov to identify potential studies for cancer patient enrollment,” Leonard Lichtenfeld, Leal advisor and former Chief Medical and Scientific Officer at the American Cancer Society, said in a statement. “The problem is that these large research hospitals, while highly reputable, do not always have clinical trials that work best for a patient’s unique medical and personal needs. Furthermore, community oncologists, who play a crucial role in providing care in communities where specialized cancer centers are less accessible, often do not have relationships with the major centers.”

Leal is the largest AI pre-screening platform for clinical trials. Leal says it has facilitated more than 4 million treatment matches, with approximately 20,000 clinical trials and 150,000 cancer patients on its platform. Leal supports over 22 cancer types, covering 95 percent of cancers.

Table of Contents

YOU MAY BE INTERESTED IN

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer. 
Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login